Fangsheng Pharmaceutical

Fangsheng Pharmaceutical was founded in June 2002. It is a high-quality, comprehensive, and research-oriented pharmaceutical and health industry group integrating pharmaceutical industry, medical services, and big health business. It has several subsidiaries. On December 5, 2014, it was successfully listed on the Shanghai Stock Exchange and formally entered the capital market (stock code: 603998). From the factory construction to now, Fangsheng has risen rapidly with steady development speed, growing into a benchmark enterprise in the pharmaceutical industry in Hunan Province. It has been successively awarded the National Torch Plan Key High-tech Enterprise, China National Medicine Top 100 Brand Enterprise, China Pharmaceutical Industry AAA Integrity Enterprise, China Outstanding Private Enterprise, National Contract-honoring and Promise-keeping Enterprise, Hunan Provincial Governor Quality Award Enterprise, and the first batch of demonstration pharmaceutical enterprises in Hunan Province.
Fangsheng takes "Your health, Fangsheng's pursuit" as its corporate mission, and takes "new drug R&D capability" as its core competitive advantage. It integrates global new drug R&D resource advantages, builds a high-level R&D team, constructs a "1+N model" new drug R&D system, and implements an integrated management and decentralized operation R&D strategy with the R&D center of Fangsheng Group headquarters as the main body and subsidiaries as support. The international, forward-looking, and holistic R&D strategic layout enables Fangsheng to achieve common development and prosperity in the three fields of traditional Chinese medicine, chemical drugs, and biological drugs. In the field of traditional Chinese medicine, Fangsheng has successfully developed several brand series products such as "Xinxue'an" brand for cardiovascular and cerebrovascular departments, "Jinbeibei" brand for pediatrics, "Meiershu" brand for gynecology, and "Fangshengtang" brand for orthopedics. In the chemical drug field, Fangsheng is committed to focusing on the development of blockbuster drugs with independent intellectual property rights and prevention and treatment of major diseases, forming core technology and innovation strength. In the biological drug field, Fangsheng holds a controlling stake in the National Engineering Research Center for Gene Drug Engineering approved by the National Development and Reform Commission in the field of genetic engineering drugs - Guangdong Jida Gene Drug Engineering Research Center, accelerating the layout speed in the biological drug field. Fangsheng currently has a nationally recognized enterprise technology center, a national postdoctoral research workstation, and the Hunan Provincial Cardiovascular and Cerebrovascular Drug Engineering Technology Research Center. It undertakes 2 major national new drug development science and technology major projects and several provincial and ministerial science and technology projects. It has obtained more than 100 drug production approvals, nearly 20 new drug certificates, and more than 20 invention patents. The rich product reserve provides strong support for realizing Fangsheng's strategy, and in the future it will provide a new commanding height for the development of Hunan and even China's pharmaceutical economy.
Fangsheng has established a nationwide marketing network and is gradually building a market sales network covering hospitals at all levels and chain and single pharmacies in various provinces, cities, and counties. While based on the domestic market, Fangsheng actively explores the international market and takes the road of internationalization. In 2016, it invested in Lipo, an American biotechnology company specializing in the R&D of anti-tumor drugs, entering the global anti-cancer drug market worth hundreds of billions of dollars, laying a solid foundation for the internationalization of pharmaceutical preparations and the entry of the Fangsheng brand into the international market.
Fangsheng has multiple production bases in Changsha, Hainan, and other places. It organizes production strictly in accordance with the new GMP and excellent performance system requirements, establishes a complete quality control and assurance system, implements whole-process and full-staff quality management, and ensures the quality and safety of people's medication. The Fangsheng Pharmaceutical Industrial Park located in Changsha High-tech Zone covers an area of 150 mu with a total construction area of 230,000 square meters. After full completion, the production capacity required for the company's strategic development will receive strong support. In the future, Fangsheng will also purchase land to build factories according to the needs of enterprise development, continuously expand production capacity, and lay a solid foundation for realizing the "century-old Fangsheng".
In recent years, on the basis of continuously developing the core business of pharmaceutical industry, Fangsheng has gradually expanded strategic sectors such as medical services and big health business. The businesses of its subsidiaries are booming, effectively achieving industrial chain integration and strategic synergy. In the future, Fangsheng will leverage the power of capital to drive industrial development, ultimately realize the "one body with two wings" strategic layout of pharmaceutical industry, medical services, and big health business, create a high-quality, comprehensive, and research-oriented big health industry aircraft carrier, realize the Fangsheng dream, and achieve the health dream!